KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Assets (2016 - 2025)

Biomarin Pharmaceutical's Other Non-Current Assets history spans 17 years, with the latest figure at $277.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 10.21% year-over-year to $277.0 million, compared with a TTM value of $277.0 million through Dec 2025, up 10.21%, and an annual FY2025 reading of $277.0 million, up 10.21% over the prior year.
  • Other Non-Current Assets for Q4 2025 was $277.0 million at Biomarin Pharmaceutical, up from $270.8 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $277.0 million in Q4 2025, with the low at $141.2 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $184.9 million, with a median of $168.3 million recorded in 2023.
  • Year-over-year, Other Non-Current Assets fell 5.03% in 2023 and then skyrocketed 46.55% in 2024.
  • Tracing BMRN's Other Non-Current Assets over 5 years: stood at $152.1 million in 2021, then grew by 15.85% to $176.2 million in 2022, then fell by 2.67% to $171.5 million in 2023, then skyrocketed by 46.55% to $251.4 million in 2024, then rose by 10.21% to $277.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Other Non-Current Assets are $277.0 million (Q4 2025), $270.8 million (Q3 2025), and $249.2 million (Q2 2025).